Myoview™ (Technetium (99mTc) Tetrofosmin)

Myoview (Technetium (99mTc) Tetrofosmin) is indicated for myocardial perfusion imaging in patients with known or suspected coronary artery disease and for the assessment of left ventricular function in patients with known or suspected heart disease.
Support

Adverse events reporting

Adverse events should be reported
Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard
Adverse events should also be reported to GE HealthCare at:
gpv.drugsafety@ge.com

Fast and efficient protocol

15-minute injection-to-image delay time1 and shorter total examination time vs sestamibi1

Image quality

Fewer repeated scans vs sestamibi, due to fewer suboptimal images resulting from liver/bowel activity2

Flexible one- or two-day protocols

Help to optimize department scheduling

Minimise radiation

Lower radiation dose vs sestamibi may help minimize patient radiation exposure3

When efficiency matters

Myoview is used as an adjunct in the diagnosis and localisation of myocardial ischaemia and/or infarction.In patients undergoing myocardial perfusion scintigraphy, ECG-gated SPECT can be used for assessment of left ventricular function (left ventricular ejection fraction and wall motion). ii) As an adjunct to the initial assessments in the characterisation of malignancy of suspected breast lesions where other tests are inconclusive.
Myoview can provide earlier and faster imaging to help your department running efficiently and enhance the image quality. It may also help minimise the patient radiation exposure.
BENEFITS

Improve efficiency and image quality

Myoview helps clinicians improve the workflow efficiency of their department and the image quality of the SPECT scans.
Fast and efficient protocols

Myoview can provide earlier and faster imaging to help your department running efficiently

Myoview allows for a 15-minute injection-to-image acquisition time, enabling efficient protocol for stress and rest imaging as well as a reduction in patient waiting time. In a prospective study by Ravizzini, Myoview demonstrated significantly shorter completion time compared to sestamibi for both rest studies and total study time.1

Myoview also required fewer repeated scans compared with sestamibi, due to fewer suboptimal images resulting from liver/bowel activity.2 Earlier imaging with Myoview is equivalent to later imaging with sestamibi when assessing subjective image quality.2 Flexible 
one- or two-day protocols with Myoview can help optimize department scheduling.

Simple preparation

Preparing Myoview is a 15-minute preparation procedure without boiling or extra dilution.
High-quality images

Image quality offers diagnostic accuracy

Myoview demonstrated high sensitivity, specificity and diagnostic accuracy.4,5,6 Clearance of Myoview from the lungs and the liver is faster than that of sestamibi, improving the resolution of early cardiac images.7

Earlier imaging with Myoview is equivalent to later imaging with sestamibi when assessing subjective image quality.2 Myoview produced a favourable heart-to-liver ratio compared with sestamibi, when imaged 30-60 minutes post-injection.2,8
Radiation exposure

The lower, approved dose range of Myoview may help minimize patient radiation exposure.

The recommended effective dose of technetium (99mTc) tetrofosmin (Myoview) per administered unit of activity to adults is 0.0058 under stress and 0.0063 at rest. In comparison, The recommended effective dose of technetium (99mTc) sestamibi (mSv/MB1) per administered unit of activity to adults is 0.0066 under stress and 0.0070 at rest.3

Support your need to efficiently visualize with efficiency and quality

Myoview can improve your image quality and workflow efficiency when localising myocardial ischaemia and infarction and assessing left ventricular function. Learn more about supporting resources available for Myoview.

Safety data for Myoview

Available for over 20 years, Myoview has a well-established and well-documented safety profile. 

Preparing Myoview

One-step, 15-minute preparation procedure without boiling makes Myoview easy and fast to prepare.

References
1. Ravizzini GC et al. Nucl Med Comm 2002; 23: 203–208. 



2. Duvall et al. J Nucl Cardiol 2020; 27: 254–265 



3. Verberne HJ et al. Eur J Nucl Med Mol Imaging 2015; 42: 1929–1940 



4. Jain D. Semin Nucl Med 1999; 29: 221–236 



5. Kapur A et al. Eur J Nucl Med 2002; 29: 1608–1616

6. Underwood S et al. Eur J Nucl Med Mol Imaging 2004; 31: 261–291

7. Acampa W et al. J Nucl Cardiol 2000; 7: 701–707.

8. Münch G et al. J Nucl Med 1997; 38: 428–432

9. Technescan MIBI (Technetium [99mTc] sestamibi) Summary of Product Characteristics (UK), Curium Pharma, August 2021.

JB03104UK